Clinical Trial Update: A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment [Phase 1]

View source ↗

Summary

This is a Phase 1 pharmacokinetic study of LY2624803 in subjects with hepatic impairment evaluating its behavior; the trial in insomnia patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• LY2624803 (LY2624803)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Insomnia | Phase 1 | Status: TERMINATED